Cargando…

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report

Detalles Bibliográficos
Autores principales:	Zerbi, Caterina, Lazic, Tanja, Sciarra, Roberta, Cristinelli, Caterina, Mazzacane, Alessandro, Carpi, Federico, Ferretti, Virginia Valeria, Gambini, Giulia, Bonfichi, Maurizio, Arcaini, Luca, Gotti, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642065/ http://dx.doi.org/10.1097/01.HS9.0000891020.48573.90

Ejemplares similares

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

P1292: MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION
por: Sciarra, R., et al.
Publicado: (2022)

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
por: Gotti, Manuel, et al.
Publicado: (2023)

Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy
por: Mo, Jiajie, et al.
Publicado: (2023)

Mutational and immunogenetic landscape of HCV‐associated B‐cell lymphoproliferative disorders
por: Defrancesco, Irene, et al.
Publicado: (2021)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

Managing Substance Use Disorder through a Walking/Running Training Program
por: Dai, Chia-Liang, et al.
Publicado: (2020)

Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma
por: De Re, Valli, et al.
Publicado: (2022)

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms
por: Fraticelli, Sara, et al.
Publicado: (2023)

Background 113
por: CERN. Geneva. Intersecting Storage Ring Division
Publicado: (1971)

113 Etüden für Violoncello = 113 studies for violoncello = 113 gyakorlat gordonkára /
por: Dotzauer, J. J. F. (Justus Johann Friedrich), 1783-1860
Publicado: (1991)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

113 Violoncello-Etüden; ausgewählt progressiv
por: Dotzauer, J. J. F. (Justus Johann Friedrich), 1783-1860

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017)

113rd LHCC Meeting
Publicado: (2013)

113rd SPSC Meeting
Publicado: (2014)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Adjudication of the Contract for the Construction of Hall 113
Publicado: (1972)

Memorandum: proposal SPSC-P-113
por: Fisher, Colin M, et al.
Publicado: (1978)

P113: INCIDENCE OF HAEMOGLOBINOPATHY IN SLOVAKIA
por: Fabryova, V, et al.
Publicado: (2022)

Health Tract, No. 113: The Morning-Prayer
Publicado: (1862)

Health Tract, No. 113: The Morning-Prayer
Publicado: (1865)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era
por: Abuelgasim, Khadega A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0gp7trb04sfvd1odehptq0is02